Day: August 30, 2022

Phase 2 to evaluate polarized dendritic cell vaccine, interferon alpha-2b, Ampligen and celecoxib for the treatment of HLA-A2+ refractory melanoma First patient dosing is expected in Q4, 2022 OCALA, Fla., Aug. 30, 2022 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced its clinical development collaborator, Roswell Park Comprehensive Cancer Center (“Roswell Park”), in a clinical trial fully funded by the National Cancer Institute (NCI), has commenced patient enrollment in its Phase 2 study in subjects with primary PD-1/PD-L1 resistant melanoma. The Phase 2 study...

VANCOUVER, British Columbia, Aug. 30, 2022 (GLOBE NEWSWIRE) — Pulse Oil Corp., (“Pulse” or the “Company”) (TSXV: PUL) is pleased to announce that the Company has filed its Q2 2022 unaudited interim financial statements and management discussion and analysis for the three month period ending June 30, 2022. Quarterly Financials for June 30, 2022 (CDN$): Some of the financial highlights of the second quarter results are provided as well as first quarter results of 2022 and the comparable results for the three month period last year are as follows:Description         June 30, 2022 March 31, 2022 * June 30, 2021Gross Revenue $1,585,097   $1,632,981 $527,552  Net income $574,523   $819,896 $(157,853)  Cashflow from operations $(134,902)   $944,526 $(27,548)  Production details:Oil (Bbl/d)Gas (Mcf/d)NGL (Bbl/d)Total...

TORONTO, Aug. 30, 2022 (GLOBE NEWSWIRE) — Nevada Zinc Corporation (“Nevada Zinc” or the “Company”) (TSXV: NZN) is pleased to provide the following operational update on its multiphase, zinc sulfate monohydrate, pilot plant project. Operational Update The Company’s multiphase pilot plant project that commenced in April 2022 has, through gravity separation, successfully produced concentrates of approximately 31% zinc. The next phase in the pilot plant project, after the production of a sufficient quantity of concentrates, is to upgrade the concentrates by downstream hydrometallurgical processes to produce zinc sulfate monohydrate that meets the requirements for use as both a fertilizer and in animal feed. The hydromettalurgical phase is scheduled to commence in mid September. The objective of this final stage of the Company’s multiphase...

NFI – Alexander Dennis electric bus 2022 NFI – Alexander Dennis electric bus 2022WINNIPEG, Manitoba, Aug. 30, 2022 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (“NFI”), a leading independent bus and coach manufacturer and a leader in electric mass mobility solutions, subsidiary Alexander Dennis Limited (“Alexander Dennis”) today announced that it has taken a second order for its new Enviro500EV electric double deck bus, this time from Hong Kong’s MTR Corporation. The zero-emission bus is scheduled for delivery in 2023. Government-owned MTR Corporation provides Hong Kong’s Mass Transit Railway urban rail system including a network of feeder bus services, for which it operates a fleet of 169 buses, most of them supplied by Alexander Dennis from its Enviro200, Enviro400, and Enviro500 vehicle...

WARMINSTER, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,427,823, which provides composition of matter patent protection for Arbutus’ AB-729 RNAi therapeutic product. The patent is expected to provide Arbutus with exclusivity for AB-729 out to at least April 2038. “We are pleased to be granted this key patent by the USPTO which expands our intellectual property estate and adds a level of protection for a fundamental asset of our chronic hepatitis B virus (cHBV) portfolio,” said William Collier, President and Chief Executive Officer of Arbutus...

The new format, called GSR (GBT Standard Rules) is planned to support advanced microchip’s nodes design rules in the areas of DRC, LVS, RV and DFM SAN DIEGO, Aug. 30, 2022 (GLOBE NEWSWIRE) — GBT Technologies Inc. (OTC PINK: GTCH) (“GBT” or the “Company”), is developing its own Integrated Circuit (IC) Design Rule Description language and format with the goal of enabling a secured, proprietary rule deck to be used in all of its current and future Electric Design Automation (EDA) tools. The GBT EDA technology is targeted to read a microchip’s process manufacturing rules, understanding its geometrical, electrical and manufacturing featured dimensions and constraints. These rules, provided by the fabrication plant, are the reference for GBT’s computer programs to analyze the IC data. This process is called IC verification and...

SAN DIEGO and TORONTO, Aug. 30, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the H.C. Wainwright 24th Annual Global Investment Conference being held in-person and virtually September 12-14, 2022, in New York City. Dr. William G. Rice, Chairman, President and CEO of Aptose, will deliver the Company presentation on Tuesday, September 13, 2022, at 11:30 a.m. ET, and with Mr. Fletcher Payne, CFO of Aptose, will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with the Aptose management team, please contact your conference representative.H.C....